Abstract:Bipolar disorder (BD) is characterized by extreme mood swings ranging from manic/hypomanic to depressive episodes. The severity, duration, and frequency of these episodes can vary widely between individuals, significantly impacting quality of life. Individuals with BD spend almost half their lives experiencing mood symptoms, especially depression, as well as associated clinical dimensions such as anhedonia, fatigue, suicidality, anxiety, and neurovegetative symptoms. Persistent mood symptoms have been associated with premature mortality, accelerated aging, and elevated prevalence of treatment-resistant depression. Recent efforts have expanded our understanding of the neurobiology of BD and the downstream targets that may help track clinical outcomes and drug development. However, as a polygenic disorder, the neurobiology of BD is complex and involves biological changes in several organelles and downstream targets (pre-, post-, and extra-synaptic), including mitochondrial dysfunction, oxidative stress, altered monoaminergic and glutamatergic systems, lower neurotrophic factor levels, and changes in immune-inflammatory systems. The field has thus moved toward identifying more precise neurobiological targets that, in turn, may help develop personalized approaches and more reliable biomarkers for treatment prediction. Diverse pharmacological and non-pharmacological approaches targeting neurobiological pathways other than neurotransmission have also been tested in mood disorders. This article reviews different neurobiological targets and pathophysiological findings in non-canonical pathways in BD that may offer opportunities to support drug development and identify new, clinically relevant biological mechanisms. These include: neuroinflammation; mitochondrial function; calcium channels; oxidative stress; the glycogen synthase kinase-3 (GSK3) pathway; protein kinase C (PKC); brain-derived neurotrophic factor (BDNF); histone deacetylase (HDAC); and the purinergic signaling pathway.

The link between alterations in circadian rhythms and lipid metabolism in bipolar disorder: the lipid droplets hypothesis

Sleep and circadian disruption in bipolar disorders: From psychopathology to digital phenotyping in clinical practice

Gut Microbial Clues to Bipolar Disorder: State‐of‐the‐art Review of Current Findings and Future Directions

Involvement of Kynurenine Metabolism in Bipolar Disorder: an Updated Review

The bipolarity of light and dark: A review on Bipolar Disorder and circadian cycles

Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi‐disciplinary literature review and agenda for future research from the ISBD task force on chronobiology

Biological rhythms are correlated with Na+, K+-ATPase and oxidative stress biomarkers: A translational study on bipolar disorder

Circadian rhythm in bipolar disorder: A review of the literature

Circadian rhythm disruptions: A possible link of bipolar disorder and endocrine comorbidities

[Relationship Between Circadian Rhythm Related Brain Dysfunction and Bipolar Disorder].

Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder

Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications

Sleep and circadian rhythm disturbance in bipolar disorder

Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets

Alterations in the Plasma Lipidome of Adult Women With Bipolar Disorder: A Mass Spectrometry-Based Lipidomics Research

Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels.

Circadian Rhythms and Sleep Disorders Associated to Major Depressive Disorder: Pathophysiology and Therapeutic Opportunities

Fibroblasts as an in vitro model of circadian genetic and genomic studies: A temporal analysis

Circadian Rhythm Dysregulation in Bipolar Spectrum Disorders

Missing a beat: assessment of circadian rhythm abnormalities in bipolar disorder in the genomic era

Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase